Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
ADC ID |
DRG0UGCKA
|
|||||
---|---|---|---|---|---|---|
ADC Name |
C12G1-DM1
|
|||||
Synonyms |
C12G1-SMCC-DM1
Click to Show/Hide
|
|||||
Drug Status |
Investigative
|
|||||
Indication |
In total 1 Indication(s)
Ovarian cancer [ICD11:2C73]
Investigative
|
|||||
Drug-to-Antibody Ratio |
5.07
|
|||||
Structure | ||||||
Antibody Name |
Anti-NECTIN2 mAb c12G1
|
Antibody Info | ||||
Antigen Name |
Nectin-2 (NECTIN2)
|
Antigen Info | ||||
Payload Name |
Mertansine DM1
|
Payload Info | ||||
Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
Linker Name |
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
|
Linker Info | ||||
Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
Combination Type |
Emtansine
|
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% (Day 30) | High NECTIN2 expression (NECTIN2+++) | ||
Method Description |
Treatments c12G1-DM1 at 1 mg/kg every 4th day by intraperitoneal injection.
|
||||
In Vivo Model | Ovarian cancer CDX model | ||||
In Vitro Model | Ovarian serous cystadenocarcinoma | SK-OV-3 cells | CVCL_0532 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% (Day 30) | High NECTIN2 expression (NECTIN2+++) | ||
Method Description |
Treatments c12G1-DM1 at 5 mg/kg every 4th day by intraperitoneal injection.
|
||||
In Vivo Model | Ovarian cancer CDX model | ||||
In Vitro Model | Ovarian serous cystadenocarcinoma | SK-OV-3 cells | CVCL_0532 | ||
Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 10.40% (Day 30) | High NECTIN2 expression (NECTIN2+++) | ||
Method Description |
Treatments c12G1-DM1 at 3 mg/kg every 4th day by intraperitoneal injection.
|
||||
In Vivo Model | Ovarian cancer CDX model | ||||
In Vitro Model | Ovarian serous cystadenocarcinoma | SK-OV-3 cells | CVCL_0532 | ||
Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 11.50% (Day 30) | High NECTIN2 expression (NECTIN2+++) | ||
Method Description |
Treatments c12G1-DM1 at 1 mg/kg every 4th day by intraperitoneal injection.
|
||||
In Vivo Model | Ovarian cancer CDX model | ||||
In Vitro Model | Ovarian cancer | Ovarian cancer cells | Homo sapiens | ||
Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 19.60% (Day 30) | High NECTIN2 expression (NECTIN2+++) | ||
Method Description |
Treatments c12G1-DM1 at 5 mg/kg every 4th day by intraperitoneal injection.
|
||||
In Vivo Model | Ovarian cancer CDX model | ||||
In Vitro Model | Ovarian cancer | Ovarian cancer cells | Homo sapiens | ||
Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 32.90% (Day 30) | High NECTIN2 expression (NECTIN2+++) | ||
Method Description |
Treatments c12G1-DM1 at 1 mg/kg every 4th day by intraperitoneal injection.
|
||||
In Vivo Model | Ovarian cancer CDX model | ||||
In Vitro Model | Ovarian adenocarcinoma | OV-90 cells | CVCL_3768 | ||
Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 46.40% (Day 30) | High NECTIN2 expression (NECTIN2+++) | ||
Method Description |
Treatments c12G1-DM1 at 3 mg/kg every 4th day by intraperitoneal injection.
|
||||
In Vivo Model | Ovarian cancer CDX model | ||||
In Vitro Model | Ovarian cancer | Ovarian cancer cells | Homo sapiens | ||
Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 84.40% (Day 30) | High NECTIN2 expression (NECTIN2+++) | ||
Method Description |
Treatments c12G1-DM1 at 3 mg/kg every 4th day by intraperitoneal injection.
|
||||
In Vivo Model | Ovarian cancer CDX model | ||||
In Vitro Model | Ovarian adenocarcinoma | OV-90 cells | CVCL_3768 | ||
Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 88.90% (Day 30) | High NECTIN2 expression (NECTIN2+++) | ||
Method Description |
Treatments c12G1-DM1 at 5 mg/kg every 4th day by intraperitoneal injection.
|
||||
In Vivo Model | Ovarian cancer CDX model | ||||
In Vitro Model | Ovarian adenocarcinoma | OV-90 cells | CVCL_3768 |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.